MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma

Abstract

Indolent primary cutaneous B-cell lymphoma is a group of malignant lymphomas comprising marginal zone B-cell lymphoma and centrofollicular B-cell lymphoma. Relapse rate of these tumors is close to 40%, and identifying those patients who are likely to progress remains a challenge. The aim of this study was to characterize the microRNA (miRNA) expression profile of a series of primary cutaneous B-cell lymphomas and correlate with histological and clinical findings. We studied a series of 68 patients with primary cutaneous B-cell lymphomas (30 cutaneous marginal-zone B-cell lymphomas and 38 primary cutaneous centrofollicular lymphomas). A set of 11 miRNAs associated with the differentiation stage of B cells was quantified by realtime PCR, using RNA extracted from formalin-fixed, paraffin-embedded tissue diagnostic samples. Relevant clinical variables were retrieved in a subset of 57 patients (28 cutaneous marginal zone B-cell lymphomas and 29 primary cutaneous centrofollicular lymphomas). miR-150 was upregulated in cutaneous marginal zone B-cell lymphomas relative to primary cutaneous centrofollicular lymphoma samples (false discovery rate o0.05). miR-155 and miR-150 expression levels were associated with progression-free survival in a univariate Cox regression analysis (Po0.1). After stratification by histological subtype, low-expression levels of miR-155 and miR-150 were both associated with shorter progression-free survival only in primary cutaneous marginal zone B-cell lymphomas cases (log-rank test, Po0.05). In summary, miRNA expression analysis can be used as a tool for diagnosis and outcome prognosis in indolent primary cutaneous B-cell lymphoma.

MicroRNA Profiling of Primary Cutaneous Large B-Cell Lymphomas

“…Although a role for microRNAs in the pathogenesis of nodal DLBCLs is generally recognized, little is known about the presence and significance of microRNAs in PCLBCL. In one recently published study, a limited set of microRNAs was investigated in PCFCL [9].…”

Role of microRNA in the pathogenesis of malignant lymphoma

“…Versus FL, MCL, and CLL with splenic involvement miR-29c NMZL Up Craig et al (60) Versus lymph node with reactive lymphoid hyperplasia FL Down Karube et al (57) t(14;18)-negative cases miR-30a BL Down Lenze et al (34) Versus DLBCL miR-30b cHL Down Navarro et al (73) Versus reactive lymph nodes miR-30d BL Down Lenze et al (34) Versus DLBCL miR-31 ATL Down NIK ⁄ NF-kB Bellon et al (53) Versus CD4+ cells cHL Down Navarro et al (73) Versus reactive lymph nodes miR-34a DLBCL Up FOXP1 Liu (59) Associated with transformation from gastric MALT to DLBCL miR-96 cHL EBV+ Down Navarro et al (73) Versus EBV-negative cHL miR-101 FL Down Karube et al (57) t(14;18)-negative cases ALCL Down Merkel et al (30) Inhibition of prolifelation in ALK(+) type (cell lines) miR-125b DLBCL Up IRF4, BLIMP1 Malumbres et al (26) in GC-enriched cells miR-128a ⁄ b cHL EBV+ Down Navarro et al (73) Versus EBV-negative cHL miR-135a cHL Down JAK2 Navarro et al (73,76) Versus reactive pymph nodes, poor outcome miR-142-3p NK ⁄ T EBV+ Down IL1A Motsch et al (77) Versus NK ⁄ T EBV(À) cells ATL Up Yin et al (52) Versus HTLV1 infected cells, versus CD4+ cells (34) Versus DLBCL MALT(gastric) Up TP53INP1 Saito et al (78) Poor reactivity to H. pylori eradication therapy miR-146a BL Down Lenze et al (34) Versus DLBCL NK ⁄ T -TRAF6 Paik et al (79) Low miR-146a patients have poor prognosis DLBCL(ABC) Up Malumbres et al (26) Versus GCB DLBCL (cell line) miR-146b BL Down Lenze et al (34) Versus DLBCL DLBCL(ABC) Up Malumbres et al (26) Versus GCB DLBCL (cell line) miR-150 MCL Down Be a et al (37) Versus CD19+ or IgD B-cells NK ⁄ T Down DKC1, AKT2 Yamanaka et al (47) Versus CD56 cells cHL Down Gibcus et al (70) Versus NHL PCMZL Down Mons alvez et al (80) Inferior PFS miR-155 MCL Up Be a et al (37) Versus CD19+ or IgD B-cells BL Down AID Kluiver et al…”

Evaluation of latent membrane protein 1 and microRNA‑155 for the prognostic prediction of diffuse large B cell lymphoma

“…miR-155-5p was also observed to be increased in Hodgkin's lymphoma, and contributed to development of the disease ( 30 ). Additionally, in indolent primary cutaneous B-cell lymphoma, Monsálvez et al ( 31 ) evaluated the association between miR-155 expression and PFS ( 31 ).…”